Overview

Natriuretic Peptides and Metabolic Risk in Obesity

Status:
Withdrawn
Trial end date:
2017-02-01
Target enrollment:
0
Participant gender:
All
Summary
The investigators are examining: 1. the relationships of insulin levels and natriuretic peptide hormone levels, and 2. the effects of administering an infusion of natriuretic peptide hormone on the breakdown of fat in healthy lean and otherwise healthy obese individuals.
Phase:
Early Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Vanderbilt University
Vanderbilt University Medical Center
Treatments:
Insulin
Insulin, Globin Zinc
Natriuretic Peptide, Brain
Criteria
Inclusion Criteria:

- Men and women ages 18-50 years

- BMI 18 to <25 kg/m2 (lean group, N=20) or BMI 30 to <40 kg/m2 (obese group, N=20)

Exclusion Criteria:

- Current use of antihypertensive medications

- Current use of glucocorticoids, metformin, or any antidiabetes medications

- Prior or current cardiovascular disease, renal disease, or liver disease

- Diabetes mellitus (taking insulin, other anti-diabetic agents, or diet-controlled)

- Atrial fibrillation

- Bleeding disorder or anemia

- Elevated LFTs

- estimuated GFR < 60 ml/min

- Abnormal sodium or potassium level

- Positive pregnancy test, women of child-bearing age not practicing birth control,
women who are breastfeeding